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ABSTRACT
Skin cancers contribute very less to the total number of carcinomas. Especially when on the face or exposed parts
affect  cosmetically  more  than  functionally.  One  of  that  is  Basal  Cell  Carcinoma  over  face;  which  rarely
metastasize. Case is reported in an adult male in a rural setup who came for cosmetic purpose. Who was treated
with best modality available in setup, wide local excision with local naso-labial flap reconstruction with follow up
for oncotherapy.
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INTRODUCTION
Basal cell carcinoma is cancer of skin, especially of
non-melanocytic origin may be of an epithelial tumor
that arises from basal cells;
1 which are small, round
cells found in the lower layer of the epidermis.
2,3
Most common sites for BCC are face; head mainly
scalp,  neck and  hand. BCC  is  the commonest  skin
cancer in human beings, which accounts for less than
0.1%  of  deaths  in  cancer.  These  tumors  are
predominant  in  sun-exposed  skin  with  its  slow
growing  nature  it metastasizes  rarely  (less  than
0.55%).
4,5 On  appearance  BCC  is  a small in  size,
raised above skin, pink or red, translucent, shiny or
waxy  lesion  and  the  area  may  bleed  with  minor
trauma. 65 - 70%  of  BCCs occurred on  the  head
(most frequently on the face), 20-25% on the trunk,
and  5%  on  the  penis,  vulva or  peri-anal  skin.
Unusually other organs may get affected.
CASE REPORT
Presenting  a  case  of  90 years normotensive non
diabetic male, farmer  by  occupation  resident  of
Sangamner  with  complaints  of  Nodular  friable
growth over Right Lateral aspect of Ala of Nose of
Right nostril since 2 years, gradually progressive to
current size, associated with itching and bleeding on
touch. It is not associated with difficulty in breathing,
difficulty  in  swallowing with  no  discharge  from
growth. No history of preceding trauma. No history
loss of appetite and weight. There was no history of
similar lesion over other body parts, no past surgical
history, and no alteration of bowel and bladder habits,
sleep and diet. No history of backache, cough, fever,
headache,  vision  abnormalities.  No  history  of
treatment  taken  for  same.  On  general  examination
patient  was  averagely  built  with  stable  vitals.    No
evidence  of  pallor  cyanosis  icterus,  clubbing  pedal
edema and lymphadenopathy. On local examination
the  lesion  was  3×1  cm  nodular  firm  growth  over
lateral edge of right ala of nose which was roughly
oval  black  in color,  slightly  tender,  bled  on  touch
with  minimal  surrounding  induration.  No  palpable
lymph  nodes  on  clinical  examination. Patient  was
evaluated investigated for same to detect Basal Cell
Carcinoma of Right ala of nose. Patient and relatives
counseled about  the  nature  of  disease  and  after
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written  and  verbal  informed consent,  patient
underwent wide local excision with Naso- Labial flap
cover  over  the  area,  postoperative  period  was
uneventful successful acceptance of naso-labial flap.
Histopathology reports suggestive  of basal cell
carcinoma. Patient was counseled and discharged for
further oncological adjuvant therapy.
DISCUSSION
Table 1: Clinico-pathologic types of BCC, each of which has a distinct biologic behavior.
3,5
Type Features
Nodular The most common type of BCC. Cystic, pigmented, keratotic and flesh colored
with telangiectases.
Infiltrative Margins  not  defined  as  tumor  infiltrates  the  dermis  in  between  the  fibrous
collagen
Micro-nodular Non ulcerative. Well defined margins.
Morpheaform Firm in consistency. Sclerotic plaques. Rarely ulcerates
Superficial Erythematous,  well  circumscribed  lesion.  Most  commonly  over  trunk  and
proximal extremities.
Table 2: Histologically, BCC is divided into the following 2 categories.
3,5
Type Features
Undifferentiated Solid BCC. Includes superficial, Sclerosing and Infiltrative.
Differentiated Differentiated BCC often has slight differentiation toward hair (keratotic BCC),
sebaceous  glands  (BCC  with  sebaceous  differentiation),  and  tubular  glands
(adenoid BCC); noduloulcerative (nodular)
Table 3: 5-Year Recurrence Rates for Primary (Previously Untreated) BCCs With Respect To Various Treatments
6
Treatment Modality Recurrence Rate
Surgical excision 10.1%
Radiation therapy 8.7%
Curettage and electro desiccation 7.7%
Cryotherapy 7.5%
All non-Mohs modalities 8.71%
Mohs micrographic surgery 1%
Primary aim of treatment is elimination of the tumor
with maximal preservation of function and physical
appearance. In  all cases  of  BCC,  surgery  is  the
recommended  treatment  modality.  Techniques  used
include Electro desiccation and curettage, Excisional
surgery,  Cryosurgery,  Mohs  micrographically
controlled surgery.  Recurrence in these cases shows
that the distance to the closest resection margin is an
important predictor.
6,7
Photodynamic  therapy  (PDT)  as  an  adjunct  is  a
reasonable choice in the following cases:
8
1. Tumor  recurrence  with  tissue  atrophy  and  scar
formation.
2. Elderly  patients  or  patients  with  medical
conditions preventing  extensive  oncoplastic
reconstructive surgery.
3. Tumor  with  poorly  defined  borders  based  on
clinical examination.
4. Tumor requiring difficult or extensive oncoplastic
surgery.
Radiation therapy: BCCs are usually radiosensitive;
radiation  therapy  (RT) is used  in  patients  with
advanced and extended lesions, as well as in those for
whom surgery is not suitable. Postoperative radiation
can  also  be  a  useful  adjunct  when  patients  have
aggressive  tumors  that  were  treated  surgically  or
when surgery has failed to clear the margins of the
tumor.
Pharmacologic therapy: Topical 5-Fluorouracil 5%,
Imiquimod, Tazarotene. The Oral Agent Vismodegib
are topical agents used in the treatment of superficial
BCC.496
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The  prognosis  for  patients  with  BCC  is  100%
survival rate for cases that have not spread to other
sites.
9 If BCC is allowed to progress, it can result in
significant  morbidity,  and  cosmetic  disfigurement
may  occur. Though BCC  is a  malignant neoplasm,
metastasize is rare. The incidence of metastatic BCC
is estimated to be less than 0.1%.  After treatment
BCC may develop in new sites after primary curative
treatment.
6
On  follow  up,  regular  skin  screenings  are
recommended as  chances  of  developing  another
tumor is as high as 35% in 3 years while 50% in next
5 years if etiology not cured.
10
Patient  and  relatives  are  counseled  for  further
prevention  of  recurrence  and  spread  of  basal  cell
carcinoma. Patients  should  avoid possible
potentiating  factors  like sun  exposure,  ionizing
radiation, arsenic ingestion, tanning beds. The regular
use of  sun-protecting  clothing  with wide-brimmed
hat,  long-sleeved  shirts and  sunglasses with  ultra-
violet [UV] protection is advised.
11
CONCLUSION
Wide local excision with naso- labial flap cover can
be  considered  for  local  basal  cell  carcinoma  over
nasal  ala  which  gives  excellent  cosmetic  results
which can be further given topical agents.
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